Phase II Single Arm Open Pilot Study to Demonstrate the Efficacy of Midostaurin in Symptom Improvement and Decrease of Mast Cell Burden in Patients With Indolent or Smoldering Systemic Mastocytosis.

Trial Profile

Phase II Single Arm Open Pilot Study to Demonstrate the Efficacy of Midostaurin in Symptom Improvement and Decrease of Mast Cell Burden in Patients With Indolent or Smoldering Systemic Mastocytosis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Midostaurin (Primary)
  • Indications Systemic mastocytosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 May 2015, as reported by ClinicalTrials.gov.
    • 18 Jan 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Mar 2015, as reported by ClinicalTrials.gov.
    • 18 Jan 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top